The Deal Register
Database › Equity financing › PHARMACORP ANNOUNCES CLOSING OF C$11.5 MILLION BOUGHT DEAL PUBLIC…

Equity financing

PHARMACORP ANNOUNCES CLOSING OF C$11.5 MILLION BOUGHT DEAL PUBLIC OFFERING

Lane
Equity financing
Announced
14 Jul 2026
Province
Saskatchewan
Industry
Unclassified
Status
Announced
What the filing says
PharmaCorp Rx Inc. (" PharmaCorp " or the " Company ") (TSXV: PCRX ) is pleased to announce that it has closed its previously announced bought deal public offering co-led by Acumen Capital Finance Partners Limited and Canaccord Genuity Corp., and including Raymond James Ltd. (collectively, the " Underwriters ") pursuant to which the Underwriters purchased, on a bought deal basis, 22,549,200 units (the " Units ") in the capital of the Company at a price of C$0.51 per Unit (the " Offering Price ") for aggregate gross proceeds to the Company of approximately C$11.5 million, which includes the…
Terms stated
exercise price, price per security
Source

The terms are in the subscriber edition

This transaction carries 2 stated terms, with the value, unit and basis of each and the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe